Asia Pacific Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)

BMIRE00030886 | Pages: 95 | Pharmaceuticals | Oct 2024 | Type: Regional | Status: Published

The Asia Pacific pharmacokinetics services market was valued at US$ 191.44 million in 2023 and is expected to reach US$ 356.58 million by 2031; it is estimated to register a CAGR of 8.1% from 2023 to 2031.

Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics Boost Asia Pacific Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the Asia Pacific pharmacokinetics services market in the near future.

Asia Pacific Pharmacokinetics Services Market Overview

The Asia Pacific pharmacokinetics services market growth in China is primarily attributed to the established pharmaceutical market, increasing R&D expenditures by pharmaceutical and biopharmaceutical companies, rising number of clinical trials due to lower operating costs, and favorable regulatory policies in place. According to the EFPIA report published in 2023, R&D expenditure by pharmaceutical companies in China grew from US$ 10,814.23 million in 2020 to US$ 12,989.23 million in 2021. China has the world's second-largest pharmaceutical market. The excessive population in the country, coupled with a rise in the cases of various noncommunicable and infectious diseases, fuels the need for new drug molecules, which makes China a prime market in Asia Pacific.

Asia Pacific Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Get more information on this report :

Asia Pacific Pharmacokinetics Services Market Segmentation

The Asia Pacific pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Asia Pacific pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Asia Pacific pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Asia Pacific pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Asia Pacific pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Asia Pacific pharmacokinetics services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific pharmacokinetics services market share in 2023.

Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; and Thermo Fisher Scientific Inc. are some of the leading companies operating in the Asia Pacific pharmacokinetics services market.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics

4.1 Market Drivers

4.1.1 Rising Prevalence of Chronic and Infectious Diseases

4.1.2 Expanding Range of Application of Pharmacokinetic Studies

4.1.3 Outsourcing of Pharmacokinetics Services to CROs

4.2 Market Restraints

4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries

4.3 Market Opportunities

4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics

4.4 Future Trend

4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services

4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Asia Pacific Analysis

5.1 Asia Pacific Pharmacokinetics Services Market Overview

5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type

6.1 Overview

6.2 Small Molecule

6.2.1 Overview

6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

6.3 Large Molecule

6.3.1 Overview

6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

6.4 Vaccines

6.4.1 Overview

6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type

7.1 Overview

7.2 Pre-Clinical ADME and Human Studies

7.2.1 Overview

7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.3 PK/PD Analysis and Reporting

7.3.1 Overview

7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.4 Dosing Simulations

7.4.1 Overview

7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.5 Risk Analysis

7.5.1 Overview

7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.6 Others

7.6.1 Overview

7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application

8.1 Oncology

8.1.1 Overview

8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.2 Infectious Diseases

8.2.1 Overview

8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.3 Neurological Disorders

8.3.1 Overview

8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.4 Autoimmune Diseases

8.4.1 Overview

8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.5 Gynecological Disorders

8.5.1 Overview

8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.6 Cardiovascular Diseases

8.6.1 Overview

8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.7 Respiratory Disorders

8.7.1 Overview

8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.8 Others

8.8.1 Overview

8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies

9.1.1 Overview

9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.2 Contract Research Organization

9.2.1 Overview

9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.3 Others

9.3.1 Overview

9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Pharmacokinetics Services Market - Country Analysis

10.1 Asia Pacific

10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.1 Overview

10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.1 Overview

10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.1 Overview

10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.4.1 Overview

10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.5.1 Overview

10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.6.1 Overview

10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

11.1 Charles River Laboratories International Inc

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Eurofins Scientific SE

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Certara Inc.

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.4 Parexel International Corp

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 Thermo Fisher Scientific Inc.

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Allucent

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 PACIFIC BIOLABS

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 SGS SA

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 Shanghai Medicilon Inc.

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms for Pharmacokinetic Services Market

 

List of Tables

Table 1. Asia Pacific Pharmacokinetics Services Market Segmentation

Table 2. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 3. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 4. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 5. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 6. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 7. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 8. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 9. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 10. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)

Table 11. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 12. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 13. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 14. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 15. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 16. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 17. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 18. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 19. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 20. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 21. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 22. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 23. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 24. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 25. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 26. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 27. Glossary of Terms

 

List of Figures

Figure 1. Asia Pacific Pharmacokinetics Services Market Segmentation, by Country

Figure 2. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

Figure 5. Asia Pacific Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)

Figure 6. Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 7. Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 8. Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 9. Asia Pacific Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)

Figure 10. Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 11. PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 12. Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 13. Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 14. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 15. Asia Pacific Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)

Figure 16. Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 17. Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 18. Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 19. Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 20. Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 21. Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 22. Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 23. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 24. Asia Pacific Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)

Figure 25. Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 26. Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 27. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 28. Asia Pacific Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)

Figure 29. Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 30. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 31. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 32. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 33. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 34. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 35. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

  1. Allucent
  2. Certara Inc.
  3. Charles River Laboratories International Inc
  4. Eurofins Scientific SE
  5. PACIFIC BIOLABS
  6. Parexel International Corp
  7. SGS SA
  8. Shanghai Medicilon Inc.
  9. Thermo Fisher Scientific Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pharmacokinetics services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific pharmacokinetics services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440